Sixteen clinical isolates of ampicillin-resistant enterococci (ARE) were recovered from the microbiology laboratory of a 450-bed rehabilitation medical center from January 1981 to September 1987. These isolates were detected when a disk diffusion test using 10 ,ug of ampicillin on a blood agar plate revealed no zones of inhibition. Tube macrodilution tests yielded an MIC of .16 ,ig of ampicillin per ml. None of the isolates were penicillinase producers by the chromogenic cephalosporin disk test. Ten isolates were Enterococcus faecium, four isolates were E. raffinosus, one isolate was E. gallinarum, and one isolate was not identified (lost). There were 6 male and 10 female patients. The sources of isolates were urine (n = 7), wound (n = 5), ascitic fluid (n = 2), blood (n = 2), peritoneal catheter tip (n = 1), Bartholin's cyst abscess (n = 1), rectal swab (n = 2), and pancreatic abscess (n = 1). The organism was isolated from multiple sites in 4 patients, was a pure culture isolate in 5 patients, and was part of a polymicrobial fora in 11 patients. Six patients were diabetic, and four had liver cirrhosis. All but four patients had received at least one antibiotic within 3 weeks of ARE isolation. The MICs (micrograms per milliliter) for 50 and 90% of isolates tested, respectively, were as follows: ampicillin, 64 and 64; penicillin, 128 and >128; vancomycin, 1 and 2; gentamicin, 4 and 16; ciprofloxacin, 1.6 and 3.2; imipenem, 128 and >128; and daptomycin (LY146032), 1.6 and 6.4. ARE may be an emerging pathogen in the hospitalized patient population.
In the past, enterococci had shown remarkable stability with regards to in vitro susceptibility to beta-lactam antibiotics. In fact, as recently as 1982, Kaye (13) commented that the susceptibility of enterococci to penicillin G and to ampicillin had not changed in the previous 20 years (31) . In 1970, Standiford et al. (30) demonstrated high-level aminoglycoside resistance (MIC, >2,000 ,uglml) among enterococcal strains that failed to show synergistic killing when exposed to combinations of penicillin and streptomycin or kanamycin. Nine years later, Moellering and his group (21) showed that Enterococcusfaecium strains accounted for the streptomycin-and amikacin-resistant isolates found clinically but that even these strains were still relatively susceptible to gentamicin and were killed readily by the penicillingentamicin combination. Sporadic reports. of E. faecium strains highly resistant to penicillin G started to appear in the literature (1, 7, 9, 18, 34) . Some of these strains were found to possess altered penicillin-binding proteins with decreased affinity to penicillin G (18, 34) . In 1983, Murray (24) reported a strain of E. faecalis highly resistant to penicillin G that produced large amounts of penicillinase. Subsequently, other ,B-lactamase-producing strains of E. faecalis were reported by separate investigators and the presence of a plasmid was demonstrated in two strains (23, 27) . Other very disturbing developments that have occurred recently among the enterococci are reports of high-level gentamicin resistance and rare isolations of vancomycin-as well as teicoplanin-resistant E. faecium (10, 16, 25, 33, 35 16 ,ug or more of ampicillin per ml were arbitrarily considered to be highly resistant.
Laboratory standard powders of the following antibiotics were used in the study: ampicillin and penicillin G (Wyeth Laboratories, Westchester, Pa.); vancomycin, streptomycin, and daptomycin (LY146032) (Eli Lilly & Co., Indianapolis, Ind.); gentamicin (Schering Corp., Kenilworth, N.J.); imipenem (Merck Sharp & Dohme, West Point, Pa.); and ciprofloxacin (Miles Laboratories, West Haven, Conn.). ,3-Lactamase production was investigated by using the nitrocefin disk method (2).
RESULTS
Sixteen patients yielded 16 isolates of ARE. The 16 isolates of ARE were identified as 10 isolates of E. faecium, 4 isolates of E. raffinosus, one isolate of E. gallinarum, and one unidentified isolate which was lost before it could be identified. MICs of >16 ,ug of ampicillin per ml were demonstrated for all 16 isolates by tube macrodilution susceptibility testing. These isolates represented less than 1% of the total enterococcal isolates recovered by our clinical microbiology laboratory. The isolates were recovered from 6 male and 10 female patients, with a mean age of 60 years (range, 17 to 86 years). Table 1 shows the clinical and microbiologie features of the 16 patients included in the study. It should be noted that one patient (no. 16) yielded ARE (E. gallinarum) from both blood and ascitic fluid. Another patient (no. 14) had blood, pancreatic abscess, and urine cultures all positive for E. faecium. A third patient (no. 15) yielded E. gallinarum from an ascitic fluid culture. These three patients, therefore, yielded ARE from body sites or fluids that are normally sterile and were therefore considered to have clinically significant infections. Seven patients yielded ARE in their urine. Four of the isolates from these bacteriuric patients were E. faecium, two were E. raffinosus, and one was unidentified. Six of the seven patients were afebrile. Five of these six afebrile and bacteriuric patients had no urinary tract symptoms, with the exception of patient no. 13 , who had complained of burning urination. Patient no. 14 had fever and chills, but this patient also had a pancreatic abscess and ARE bacteremia. Five of these patients received no therapy for ARE bacteriuria. One of these patients was transferred to another hospital with no subsequent follow-up, two patients had spontaneous disappearance of ARE without therapy, and two others had no repeat urine cultures taken.
Among the 10 patients who yielded ARE from sources other than urine or rectal swabs ( Five isolates were recovered in pure culture, and eleven were isolated with other microorganisms. Five were isolated with one other organism, three were isolated with two other organisms, and three were isolated with three other organisms. The accompanying organisms were coagulase-negative staphylococcus (n = 4), Escherichia coli (n = 4), Proteus mirabilis (n = 2), Pseudomonas aeruginosa (n = 2), Klebsiella oxytoca (n = 2), Klebsiella pneumoniae (n = 1), ampicillin-susceptible enterococci (n = 2), Candida tropicalis (n = 1), Candida albicans (n = 1), and viridans group streptococci (n = 1).
Diabetes mellitus (n = 6; four insulin-dependent isolates) and alcoholic liver disease (n = 4) were the most frequently present underlying diseases.
Twelve of the sixteen patients had received at least one antimicrobial agent for at least 72 h within 3 weeks prior to ARE isolation ( (22) . Most of this resistance has been attributed to production of streptomycin-modifying enzymes encoded by plasmid determinants (6, 15) . Highlevel resistance to kanamycin and amikacin and, more recently, to gentamicin has also been reported (11, 19, 25, 35) . These aminoglycoside-resistant isolates have been shown to lose the bactericidal synergy demonstrated by their susceptible counterparts with combinations of aminoglycosides and penicillin or vancomycin. Most of these aminoglycoside-resistant isolates have been E. faecium.
A cause of serious concern has been the description of P-lactamase production in isolates of E. faecalis in recent years (23, 24, 27 4 ,ug of ampicillin per ml and 8 ,ug of penicillin G per ml (13, 14, 32 The significance of the isolation of ARE in clinical specimens may be questioned, especially when the enterococcus is part of a polymicrobial flora. However, as seen in this study, ARE was isolated from normally sterile body fluids or sites, including blood, ascitic fluid, and pancreatic tissue. The organism was also isolated in pure culture four times from the urine. We are continuing to monitor infections caused by ARE in our facility.
The possibility that high-level ampicillin resistance in enterococci can become a much more common occurrence is a matter of great concern. Currently, the only established alternative antimicrobial agent for the treatment of infections due to ARE has been vancomycin. If resistance to vancomycin also becomes a problem, our choices would be severely limited. Some possible options include ciprofloxacin (3, 5, 29) and imipenem (5, 7). However, the clinical experience in the treatment of enterococcal infections with these antimicrobial agents is quite limited, and E. faecium isolates, unlike E. faecalis isolates, are characteristically resistant in vitro to imipenem. Our present report also shows that other non-E. faecalis ARE species may also be resistant to imipenem.
Daptomycin, an experimental lipopeptide antibiotic, has shown impressive activity in vitro, as well as in vivo (in experimental animals), against enterococci (20, 28) . This antibiotic may be a viable alternative in the treatment of ARE infections in the future, and further studies with this drug are indicated.
It remains to be seen whether these non-,B-lactamaseproducing ARE are destined to be significant clinical problems nationwide. All of our ARE isolates belonged to species other than E. faecalis. It is unclear whether ampicillin resistance in ARE due to mechanisms other than 1-lactamase production will remain confined to the non-E. faecalis species. We do believe that our experience should prompt other institutions and clinicians to be fully aware of the possible emergence of these organisms in their own institutions. The mechanism(s) of resistance to ampicillin and penicillin in these strains should be elucidated in the future.
